Congrats Dr. Vanuytsel @CReM_Boston: BMC Researcher Aims to Build More Options, Access for Sickle Cell Disease Treatment - HealthCity https://t.co/fptrddMwlS
So excited to share that the first paper from the Lung Disease Lab is now published in JCI Insight!
I’m exceptionally grateful to all our collaborators and proud of the team, particularly Declan Turner for driving this work over the line!
Read more here: https://t.co/GI9kXGRA9v
Our latest work from The KottonLab, just out now, focused on lung endothelium:
"A chimeric human-mouse lung vascular model using induced pluripotent stem cells reveals insights into the pathogenesis of BMPR2-related pulmonary hypertension" https://t.co/GvefkcD3V0
Our hands-on cell culture course @CReM_Boston for making lung out of iPSCs has kicked off and is running all week. Those smiles you see are from day 2: making endoderm, the first step to engineering lung epithelium! #itsthecells! #helpisontheway! @BU_Tweets@The_BMC
Miriam O'Day, A1F Senior Policy Consultant, is representing the Alpha-1 Foundation at the 2026 NORD Rare Disease Scientific Symposium in Arlington, VA. This year's theme, "Advancing Innovation in Rare Disease Research," brings together a dynamic community of researchers, clinicians, industry leaders, and advocates to spark the conversations and connections that drive science forward. @RareDiseases
Congratulations to Dr. Christine Reardon for receiving the Henry D. Chadwick Medal at MTS 2026! You are so loved by your colleagues, trainees, and patients. We thank you for your expertise in intensive care medicine, lung cancer, and neuromuscular respiratory disease.
Congrats to Dr. Andrew Wilson's Lab and MD/PhD student/first author, Carly Merritt on their new paper: "AT2-intrinsic Z-AAT expression drives conserved inflammatory and proteotoxic stress responses and predisposes to emphysema" https://t.co/JUsqoZ7ij5
Congratulations to Dr. Chris Reardon, this years Chadwick Medal awardee @MassThoracic 2026! Our once and always program director @The_BMC Pulmonary.
Today, Beam announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency (AATD) and the selection of 60 mg as the optimal biological dose to advance into pivotal development to support potential accelerated approval.
The Kotton Lab announces our latest biorxiv posting; a collaboration with the labs of Jessie Huang @hjhjess and Will Zacharias. "The chromatin remodeling complex PRC2 safeguards cell fate in alveolar epithelial type 2 cells" https://t.co/Th942m3R2r
Such a treat to tell our story of how discovering a previously unknown mechanism that controls IPF alveolar epithelial stem cell regeneration also enhances lung resilience against viral infection.
We are back with the 4th edition of this fantastic lung meeting and what a busy day the #FusionLung26 crowd have had!
Amazing talks, sharp questions, and lots of ideas to take back to the lab. We even made time for a quick snorkelling excursion along the beautiful Playa Mujeres coastline 🚤
🔬We are wrapping up this inspiring day with our first fantastic poster session and dinner!
Bidirectional fibrogenic cross-talk revealed in a human iPSC-derived epithelial-mesenchymal co-culture model of pulmonary fibrosis https://t.co/LQHcu3o9nG
The Kotton Lab is pleased to announce our latest work, just out @biorxivpreprint. Congrats to first author, Andrea Alber and all the team @CReM_Boston ! https://t.co/LQHcu3o9nG
Just out @AJRCMB, our review of how axolotl salamander lung regeneration offers many hints for advancing human lung regeneration research for our patients:
https://t.co/2cizo0vIsn
Thanks to first author, Aaron Dobie @CReM_Boston and senior author James Monaghan @monaghan_lab!
Thrilled to host Dr. Hao Zhu @CReM_Boston as this year's 10th anniversay Annual Anita Kurmann Memorial Lecturer! Inspiring science from the @Zhu_Lab in Anita's honor. #itsthecells